AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
AstraZeneca has inked a deal worth “up to” $555 million
The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer
Madrid has put blood pressure back on the biotech map.
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
In the high-stakes world of biotechnology, big pharma acquisitions often
EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)
European biotech received a confidence boost as the EU’s European
Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up
A few years ago, Emergent BioSolutions’ Bayview plant in Baltimore
AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development
AstraZeneca has completed its planned equity investment in Cellectis, a
MOST POPULAR
